Study Evaluating the Safety and Tolerability of NSA-789

Wyeth

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: NSA-789; Drug: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00633048

3230A1-1000

Details and patient eligibility

About

This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.

Enrollment: 64 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• Healthy men and women between 18 and 50 years old.
• Women must be of non-child-bearing potential (not able to have children).
• Must be of normal body weight.

Trial design

64 participants in 2 patient groups, including a placebo group

NSA-789

Experimental group

Description:

active drug

Treatment:

Drug: NSA-789

placebo

Placebo Comparator group

Description:

placebo

Treatment:

Drug: placebo